tetano
Editor, Senior Moderator
J Infect Dis. 2012 Oct 19. [Epub ahead of print]
Localized mucosal response to LAIV in adults.
Barr?a MI, Garrido JL, Stein CR, Scher E, Ge Y, Engel SM, Kraus TA, Banach DB, Moran TM.
Source
Department of Microbiology, Mount Sinai School of Medicine, New York, NY, 10029 USA.
Abstract
Background. Influenza infection is a major public health burden worldwide. Available vaccines include the inactivated intramuscular trivalent vaccine and, more recently, a live attenuated intranasal vaccine (LAIV). The measure of successful vaccination with the inactivated vaccine is a systemic rise in IgG but for the LAIV no such correlate has been established.Methods. Seventy nine subjects were given the live, attenuated intranasal influenza vaccine FluMist. Blood was collected prior to vaccination and 3 days and 30 days post-vaccine. Nasal wash was collected 3 days and 30 days post-vaccine. Responses were measured systemically and in mucosal secretions for cytokines, cell activation profiles and antibody responses.Results. Only 9% of subjects who received LAIV seroconverted, while 33% of patients developed at least a two-fold increase in influenza specific IgA antibodies in nasal wash. LAIV induced a localized inflammation as suggested by increased expression of interferon response genes in mucosal RNA and increased G-CSF and IP10 in nasal wash. Interestingly, patients who seroconverted had significantly lower pre-vaccine serum G-CSF.Conclusions. Protection by LAIV is likely provided through mucosal IgA and not by increases in systemic IgG. LAIV induces local inflammation. Seroconversion is achieved in a small fraction of subjects with lower serum G-CSF.
PMID:
23087433
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23087433
Localized mucosal response to LAIV in adults.
Barr?a MI, Garrido JL, Stein CR, Scher E, Ge Y, Engel SM, Kraus TA, Banach DB, Moran TM.
Source
Department of Microbiology, Mount Sinai School of Medicine, New York, NY, 10029 USA.
Abstract
Background. Influenza infection is a major public health burden worldwide. Available vaccines include the inactivated intramuscular trivalent vaccine and, more recently, a live attenuated intranasal vaccine (LAIV). The measure of successful vaccination with the inactivated vaccine is a systemic rise in IgG but for the LAIV no such correlate has been established.Methods. Seventy nine subjects were given the live, attenuated intranasal influenza vaccine FluMist. Blood was collected prior to vaccination and 3 days and 30 days post-vaccine. Nasal wash was collected 3 days and 30 days post-vaccine. Responses were measured systemically and in mucosal secretions for cytokines, cell activation profiles and antibody responses.Results. Only 9% of subjects who received LAIV seroconverted, while 33% of patients developed at least a two-fold increase in influenza specific IgA antibodies in nasal wash. LAIV induced a localized inflammation as suggested by increased expression of interferon response genes in mucosal RNA and increased G-CSF and IP10 in nasal wash. Interestingly, patients who seroconverted had significantly lower pre-vaccine serum G-CSF.Conclusions. Protection by LAIV is likely provided through mucosal IgA and not by increases in systemic IgG. LAIV induces local inflammation. Seroconversion is achieved in a small fraction of subjects with lower serum G-CSF.
PMID:
23087433
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23087433